Iambic could earn almost $2 billion in new Takeda deal

Iambic Therapeutics has secured a major collaboration with Takeda Pharmaceutical to utilize its AI models for discovering small-molecule drugs targeting oncology and inflammatory conditions. The deal could generate over $1.7 billion in payments and royalties for the San Diego-based startup.